In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery

Jeremy Clark; Steven Y C Tong

doi:10.7326/J23-0025

In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery

Ann Intern Med. 2023 May;176(5):JC52. doi: 10.7326/J23-0025. Epub 2023 May 2.

Authors

Jeremy Clark¹, Steven Y C Tong¹

Affiliation

¹ Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.).

PMID: 37126816
DOI: 10.7326/J23-0025

Abstract

McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329:296-305. 36633838.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Double-Blind Method
Fluvoxamine* / adverse effects
Fluvoxamine* / therapeutic use
Humans
Outpatients

Substances

Fluvoxamine